SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Depression	Dishevelled dsh homolog 1 (DVL1; DVL); glycogen synthase kinase 3β (GSK3β)	Mouse studies suggest increasing DVL expression or inhibiting GSK3β could help treat depression. In mice susceptible to depression and in postmortem brain tissue from depression patients, DVL levels were lower than those in controls. In the mouse model, overexpression of Gsk3β decreased Dvl signaling and increased susceptibility to depression compared with overexpression of control protein. Next steps include developing small molecules that target the DVL-GSK3β pathway. DiaMedica Inc.'s DM-99, a GSK3β inhibitor, is in Phase II testing to treat diabetes. Neurim Pharmaceuticals Ltd.'s GSK3β inhibitor, Neu-120, is in Phase II testing to treat Parkinson's disease (PD). *SciBX* 4(26); doi:10.1038/scibx.2011.743 Published online June 30, 2011	Findings unpatented; licensing status not applicable	Wilkinson, M.B. *et al. J. Neurosci.*; published online June 22, 2011; doi:10.1523/JNEUROSCI.0039-11.2011 **Contact:** Eric J. Nestler, Mount Sinai School of Medicine, New York, N.Y. e-mail: eric.nestler@mssm.edu